Search Results

1 Chairman and CEO's Letter 2 CSL Calendar 2 2019 Performance 4 2019 Business performance and highlights 4 14 August Annual profi t and fi nal dividend announcement Financial highlights 5 10 September Shares traded ex-dividend 3 Our Company 6 11 September Record date for fi nal dividend Our businesses 6 Our locations 7 11 October Final dividend paid Our product portfolio 8 16 October Annual General Meeting Our research and development pipeline 9 31 December Half year ends 4 CSL Strategy 10 2020 How we create value 12 12 February Half year profi t and interim dividend 5 Powered by Innovation 14 announcement Collaboration with and funding of medical research 14 11 March Shares traded ex-dividend Investment in research and development pipeline 14 12 March Record date for interim dividend Focus on selected therapeutic areas - specialisation 15 9 April Interim dividend paid New products to market 16 30 June Year ends Clinical trials in process and new 18 19 August Annual profi t and fi nal dividend announcement Clinical trial transparency 18 10 September Shares traded ex-dividend Leveraging advanced analytics and artifi cial intelligence 19 11 September Record date for fi nal dividend Innovation across the value chain 19 9 October Final dividend paid 6 Global Reach and Impact 21 14 October Annual General Meeting Global reach and focus 21 31 December Half year ends Donor management 24 Focus on effi ciency, standardised manufacturing 24 processes and integrated supply chain Annual General Meeting Environment health and safety 25 Wednesday, 16 October 2019 at 1 p.m. Supply chain management 25 7 A Trusted Health Partner 26 New city and venue Product quality and safety 26 Value and access 27 The Westin Sydney, Grand Ballroom Public policy engagement 28 1 Martin Place Secure and reliable supply 29 Sydney NSW 2000 Pandemic and emergency response 29 Relationships with healthcare professionals 29 Share Registry regulators and patient groups Computershare Investor Services Pty Limited Responsible marketing and promotion 29 Postal Address:

In Canada, Ferinject ® is commercialized through CSL Behring Canada, Inc., with availability expected in the second half of 2024.

The collaborative group brings together stakeholders in U.S. health care who want to improve access to care and outcomes for sickle cell patients.

The number of Rights granted is equivalent to the fee sacrificed divided by the prevailing market price of CSL shares at that time Rights are allocated in two tranches and vesting occurs following the disclosure of half year and full year financial results following the grant of Rights.

4 October Final dividend paid 11 October Annual General Meeting 31 December Half Year ends Find out more CSL.com 2024 14 February Half Year results and interim dividend announcement 11 March Shares trade ex-dividend About this report 12 March Record date for interim dividend This Annual Report combines CSL's fi nancial and non-fi nancial performance in one comprehensive account, linking our sustainability 3 April Interim dividend paid and strategic priorities to our business results.

A world-class facility for 500 researchers is set to open in Marburg in the second half of 2022.

11 September Record date for fi nal dividend 9 October Final dividend paid 14 October Annual General Meeting 31 December Half Year ends Find out more 2021 Key Dates CSL.com 16 February Half year profi t and interim dividend announcement 4 March Shares traded ex-dividend About this report 5 March Record date for interim dividend This is CSL's second annual report where we have combined our 1 April Interim dividend paid financial and non-financial performance in one comprehensive 30 June Full Year ends account, linking our sustainability and strategic priorities to our business results.

Production of the vaccine candidate, developed by the University of Oxford and AstraZeneca, is underway in Australia.

Revenue and Expenses of the contingent payments has been changed as better information On 14 May 2018 CSL acquired 100% of the equity of Guangzhou Junxin is available since the half year accounts provisional accounting.

With almost half our workforce operating remotely, we have been able to mitigate the need for the urgent and tight demands on suppliers, utilising existing reserves and procuring early for long-term demand.